BillionToOne stock

BillionToOne Stock

HealthTech
Looking to sell BillionToOne Stock or Options? Get a free valuation
Founded: 2016Funding to Date: $408M
Visit website

BillionToOne is a molecular diagnostics company that aims to create prenatal and oncology assays with unparalleled sensitivity and precision. It provides an ultra-sensitive comprehensive genomic profiling assay that identifies more actionable mutations for selecting treatments. BillionToOne also offers a pan-cancer tumor-naive oncology test, which accurately measures tumor burden from a blood sample to monitor therapy response. Their prenatal tests offer more than simple aneuploidy detection, identifying single-gene disorders like sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a straightforward blood test.

Investors Include:

Shahram Seyedin-Noor, Keyan Li, Adams Street Partners, Pacific 8 Ventures, Metaplanet Holdings, Endpoint Ventures, Lombardstreet Ventures, NewDo Venture, 500 Emerging Europe, Hummingbird Ventures, Baillie Gifford, Start Capital, U.S. Department of Health and Human Services, Enis Hulli, Norwest Venture Partners, Sandy Kory, 500 Global, Civilization Ventures, Wei Guo, MengKe Li, Rina Onur, Luigi Bajetti, Neuberger Berman, Eczacıbaşı Momentum, Lawrence Diao.

Own BillionToOne stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure